Survival with Dacarbazine and Fotemustine in Glioblastoma
Author Information
Author(s): Fazeny-Dörner B, Veitl M, Wenzel C, Rössler K, Ungersböck K, Dieckmann K, Piribauer M, Hainfellner J, Marosi C
Primary Institution: University of Vienna
Hypothesis
Does the combination of dacarbazine and fotemustine improve survival in newly diagnosed glioblastoma multiforme patients?
Conclusion
The combination of dacarbazine and fotemustine with radiotherapy resulted in a median survival of 14.5 months for patients with newly diagnosed glioblastoma multiforme.
Supporting Evidence
- 42% of patients were alive at the time of study evaluation.
- The median survival was 72 weeks, which is approximately 14.5 months.
- 12-month survival rate was 58%, and 24-month survival rate was 23%.
- Major toxicity observed was thrombocytopenia, affecting several patients.
Takeaway
This study looked at how two medicines, dacarbazine and fotemustine, can help people with a serious brain cancer called glioblastoma live longer when used with radiation treatment.
Methodology
Patients with newly diagnosed glioblastoma were treated with dacarbazine and fotemustine alongside radiotherapy, and their survival and response to treatment were monitored.
Limitations
The study had a small sample size and was limited to a specific patient demographic.
Participant Demographics
The median age of participants was 44 years, with a gender distribution of 16 females and 39 males.
Statistical Information
Confidence Interval
28–116 weeks
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website